Thrombopoietin Levels and Platelet Transfusion in Neonates
NCT ID: NCT00549484
Last Updated: 2008-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2003-05-31
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898
Childhood Reactive Thrombocytosis
NCT01230528
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
NCT00412464
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
NCT03939637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We hypothesize that a decrease in plasma TPO levels will be seen following a platelet transfusion in a population of neonates with thrombocytopenia. We also hypothesize that a platelet transfusion of 15 mL/kg will result in a greater rise in platelet count than a transfusion pf 10 mL/kg of platelets.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
10 mL/kg platelet transfusion
No interventions assigned to this group
2
15 mL / kg platelet transfusion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decision made by medical team to transfuse with platelets
Exclusion Criteria
6 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Christiana Care Health Services
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christiana Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex Kline, MD
Role: PRINCIPAL_INVESTIGATOR
Christiana Hospital
David A. Paul, MD
Role: PRINCIPAL_INVESTIGATOR
Christiana Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Christiana Hospital
Newark, Delaware, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCC#23049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.